Main Products
Chugai’s prescribed medicines are categorized into oncology and Specialty (excl. oncology).
View details in a PDF format.
Oncology Area
| Alecensa® (alectinib) | ALK inhibitor |
|---|---|
| Avastin® (bevacizumab) | Anti-VEGF humanized monoclonal antibody |
| FoundationOne® CDx Cancer Genomic Profile FoundationOne® Liquid CDx Cancer Genomic Profile |
- |
| Gazyva® (obinutuzumab) | Anti-CD20 humanized monoclonal antibody |
| Herceptin® (trastuzumab) | Anti-HER2 humanized monoclonal antibody |
| Kadcyla® (trastuzumab emtansine) | Anti-HER2 antibody-tubulin polymerization inhibitor conjugate |
| Perjeta® (pertuzumab) | Anti-HER2 humanized monoclonal antibody |
| Polivy® (polatuzumab vedotin) | Antimicrotubule binding anti-CD79b monoclonal antibody |
| Rituxan® (rituximab) | Anti-CD20 monoclonal antibody |
| Rozlytrek® (entrectinib) | Tyrosine kinase inhibitor |
| Tecentriq® (atezolizumab) | Anti-PD-L1 humanized monoclonal antibody |
Specialty Area (excl. Oncology)
| Actemra® (tocilizumab) | Humanized anti-human IL-6 receptor monoclonal antibody |
|---|---|
| CellCept® (mycophenolate mofetil) | Immunosuppressant |
| Edirol® (eldecalcitol) | Osteoporosis agent (Active vitamin D3 derivative) |
| Enspryng® (satralizumab) | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody |
| Evrysdi® (risdiplam) | Spinal muscular atrophy agent |
| Hemlibra® (emicizumab) | Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody |
| Mircera® (epoetin beta pegol) | Long-acting erythropoiesis-stimulating agent |
| Oxarol® (maxacalcitol) | Agent for secondary hyperparathyroidism |
| Ronapreve® (casirivimab/imdevimab) | anti-SARS-CoV-2 monoclonal antibody |
| Tamiflu® (oseltamivir) | Anti-influenza agent |
| Vabysmo® (faricimab) | Anti VEGF/anti Ang-2 bispecific antibody |
